Equities

Avantor Inc

Avantor Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)20.38
  • Today's Change0.235 / 1.17%
  • Shares traded2.82m
  • 1 Year change+2.90%
  • Beta1.3019
Data delayed at least 15 minutes, as of Nov 21 2024 19:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Avantor, Inc. is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. Its segments include Laboratory Solutions and Bioscience Production. Its products include materials and consumables, equipment and instrumentation, and services and specialty procurement. Materials and consumables include chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits and education and microbiology and clinical trial kits, and peristaltic pumps. Equipment and instrumentation include filtration systems, virus inactivation systems, analytical instruments, freezers, and biological safety cabinets. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.

  • Revenue in USD (TTM)6.82bn
  • Net income in USD309.60m
  • Incorporated2016
  • Employees14.50k
  • Location
    Avantor IncBuilding One100 W Matsonford Rd Ste 200RADNOR 19087United StatesUSA
  • Phone+1 (610) 386-1700
  • Fax+1 (302) 636-5454
  • Websitehttps://www.avantorsciences.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Bruker Corp3.24bn304.90m8.09bn9.71k25.734.4817.142.502.072.0721.8911.920.65271.515.73333,913.706.128.388.1411.4049.3149.859.3811.390.708526.830.55499.8117.149.3644.0318.9116.794.56
Teleflex Inc3.03bn238.01m8.70bn14.50k37.161.9417.242.885.045.0364.0196.500.4042.116.76208,677.503.185.863.466.4255.9954.437.8714.621.396.610.281815.846.573.97-1.4712.732.510.00
Masimo Corp2.04bn78.60m8.83bn3.80k113.456.0350.964.321.451.4537.7227.350.67151.775.52537,526.302.588.653.2310.3150.0557.303.8512.031.112.840.34560.000.604219.00-43.21-15.9631.06--
Bio Rad Laboratories Inc2.58bn-778.69m9.12bn8.03k--1.21--3.53-27.32-27.3290.77267.460.22941.495.61321,321.20-6.929.08-7.269.6054.4355.55-30.1841.974.520.26120.13830.00-4.673.1382.43--3.83--
Penumbra Inc1.16bn34.55m9.18bn4.20k278.078.31150.747.890.86020.860229.7128.780.78971.046.08277,089.502.342.322.612.6165.7063.902.973.173.25--0.02180.0024.9518.934,643.1668.609.64--
Henry Schein, Inc.12.50bn314.00m9.19bn25.00k30.192.6315.530.73552.442.4496.8927.991.224.777.73499,960.002.976.094.8610.4431.5930.042.424.400.8176.230.3480.00-2.445.55-22.68-0.145621.27--
Solventum Corp8.22bn720.00m11.81bn22.01k16.423.709.341.444.164.1647.4518.480.58313.937.19373,290.305.11--6.03--56.38--8.76--0.82685.020.7176--0.8241--0.2234------
Globus Medical Inc2.48bn91.51m13.26bn5.00k125.962.7937.905.350.66360.663618.0829.940.47471.284.58495,719.201.756.901.997.4558.1471.733.6914.051.64--0.09740.0053.3417.08-35.39-4.725.57--
Revvity Inc2.72bn258.26m13.55bn11.50k53.151.7219.734.982.092.0622.0664.880.20782.894.37236,657.001.974.762.155.3955.4457.199.4915.342.9711.960.28696.52-16.95-0.1982-64.99-5.28-2.690.00
Avantor Inc6.82bn309.60m13.71bn14.50k44.332.4719.182.010.45440.454410.018.160.5325.566.09470,331.002.422.972.753.3533.5333.444.545.061.063.290.46980.00-7.263.51-51.52--31.17--
Baxter International Inc11.77bn225.00m16.65bn60.00k73.822.1212.701.410.4420.21423.1015.420.41052.915.42196,133.300.81980.19421.050.233338.4338.202.000.36741.093.810.61961,398.942.125.9497.15--0.9829.71
Align Technology, Inc.3.96bn441.57m16.71bn21.61k38.164.2428.714.225.875.8752.6352.760.62454.324.14183,272.506.9616.3410.3924.1469.9871.7211.1523.161.14--0.000.003.4214.4523.092.15-4.46--
Hologic Inc4.03bn789.50m18.13bn6.99k23.503.5316.504.503.323.3216.9722.090.44062.726.57--8.6313.129.8415.2056.2560.8219.5924.753.0364.450.3307---0.00253.6673.14--4.30--
Insulet Corp1.98bn420.90m18.70bn3.00k46.3416.7237.479.435.755.7525.9615.940.72231.426.14661,300.0015.322.7118.563.1469.3665.8121.224.282.8098.710.55570.0030.0224.664,384.78128.77-7.63--
Data as of Nov 21 2024. Currency figures normalised to Avantor Inc's reporting currency: US Dollar USD

Institutional shareholders

53.36%Per cent of shares held by top holders
HolderShares% Held
Dodge & Coxas of 30 Sep 202468.42m10.05%
T. Rowe Price Investment Management, Inc.as of 30 Sep 202467.10m9.86%
The Vanguard Group, Inc.as of 30 Sep 202461.15m8.98%
BlackRock Fund Advisorsas of 30 Sep 202453.72m7.89%
SSgA Funds Management, Inc.as of 30 Sep 202422.37m3.29%
Barrow, Hanley, Mewhinney & Strauss LLCas of 30 Sep 202421.59m3.17%
Canada Pension Plan Investment Boardas of 30 Sep 202420.92m3.07%
Boston Partners Global Investors, Inc.as of 30 Sep 202419.13m2.81%
Janus Henderson Investors US LLCas of 30 Sep 202417.65m2.59%
Geode Capital Management LLCas of 30 Sep 202411.15m1.64%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.